Adapting Social Neuroscience Measures for Schizophrenia Clinical Trials, Part 3: Fathoming External Validity
Article Dec 03, 2013
Charles M. Olbert, David L. Penn, Robert S. Kern, Junghee Lee, William P. Horan, Steven P. Reise, Kevin N. Ochsner, Stephen R. Marder, Michael F. Green
Abstract:It is unknown whether measures adapted from social neuroscience linked to specific neural systems will demonstrate relationships to external variables. Four paradigms adapted from social neuroscience were administered to 173 clinically stable outpatients with schizophrenia to determine their relationships to functionally meaningful variables and to investigate their incremental validity beyond standard measures of social and nonsocial cognition. The 4 paradigms included 2 that assess perception of nonverbal social and action cues (basic biological motion and emotion in biological motion) and 2 that involve higher level inferences about self and others’ mental states (self- referential memory and empathic accuracy). Overall, social neuroscience paradigms showed significant relationships to functional capacity but weak relationships to community functioning; the paradigms also showed weak correlations to clinical symptoms. Evidence for incremental validity beyond standard measures of social and nonsocial cognition was mixed with additional predictive power shown for functional capacity but not community functioning. Of the newly adapted paradigms, the empathic accuracy task had the broadest external validity. These results underscore the difficulty of translating developments from neuroscience into clinically useful tasks with functional significance.
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Classically, the “amyloid” hypothesis, which ties the disease’s spread to that of amyloid protein, is thought to underlie AD’s pathology. After years of mixed to negative results in clinical trials, new research is underway to investigate what role the brain’s own immune system plays in amyloid-driven disease; an “infl-amyloid” hypothesis.
To pick apart the differences between individual cells in complex multicellular organisms, we need to look at cells one-by-one. This article takes a look at how several scientists in North America are using single cell proteomics (SCP) technologies to discern disease pathogenesis and enhance directed stem-cell differentiation.READ MORE